Image Source: AsiaOne
Sun BioPharma Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic CancerGlobeNewswireApril 03, 2020MINNEAPOLIS, MN, April 03, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced it will pause enrollment in its ongoing clinical trial of SBP-101. The COVID-19 pandemic has affected the conduct of clinical trials at our US and Australian sites. Some cancer centers have redeployed resources to prioritize COVID-19 patient care activities.
Source: AsiaOne